About Us

Tracery is a clinical stage ophthalmic imaging & health data analytics company specializing in Precision Medicine and Customized Clinical Trial design, currently focused on Age Related Macular Degeneration (AMD).

For diseases of the eye, biopsy is not possible, so there is a reliance on imaging technology, which poses a significant challenge of drug development, and requires the incorporation of image-based biomarkers (IBB).

Dry AMD is a complex disease of innate immunity, oxidative stress and lipid dysregulation that relies on IBBs. Unfortunately, the only measure as a clinical trial endpoint is the standard Fundus Autofluorescence (FAF) which can only measure tissue after it is lost, limiting prevention studies.

There is an enormous need for better biomarkers and measures of disease.

To address this need, Tracery is pursuing Precision Drug Development: putting the right patient in the right study, targeting the right biology, evaluating the right chemistry. In fields where inadequate or no treatments exist, this is the first step in Personalized Medicine: treating the right patient with the right medicine for them.

Our platform is composed of 3 core parts:

1. Providing new Image-Based Biomarkers using our own novel technology

2. Incorporating patients’ personal health data (eg. from health records, genetic analysis and more)

3. Enabling for in silico drug design, to predict new potential drugs hat target the OMICs-associated pathway based on a patient’s IBBs.

Dr. Shelley Boyd runs Canada’s only High-Risk dry AMD Clinic. All studies are carried out at the ophthalmology Patient Education & Research Centre (Eye-PERC) established by Dr. Boyd, and in conjunction with St. Michael’s Hospital. The clinic focuses on patient education, risk modification and research.

State of the art imaging equipment allows us to carefully describe the stage of dry AMD and to further identify your particular phenotypes of disease. This information is vital for correlating subtypes of dry AMD against possible underlying causes and risk of progression.

1) Dry AMD Registry: Enrols patients referred with a diagnosis of high-risk dry AMD and wishing to participate in our research registry. These patients may ultimately be selected to participate if any new studies are initiated.

2) Visualization of Active Tumour Associated Macrophages: A pilot project using Tracery’s imaging method takes specialized images of patient eyes, to determined whether specific cells of the innate immune system can be labelled in vivo in the eyes of patients

3) Role of inflammation in AMD and other retinal disorders: Using Tracery’s imaging method to take specialized images of patient eyes, looking for sites of active inflammation. Results from this study are helping understand the role of innate immunity in AMD and other ophthalmic disorders.

Information for Patients

All patients must be referred by their own eye care specialist

Information for Referring Physicians

Download referral form